Journal Home
Search for

Volume 16, Issue 2, Pages e1-e6 (April 2006)


View previous. 25 of 25

Renal Vitamins

Pam Buchholz, RD, CDabCorresponding Author Information

Article Outline

Thiamin (B1), Riboflavin (B2), Pantothenic Acid (B5)

Niacin (B3)

Folic Acid, Cobalamin (B12), Pyridoxine (B6)

Biotin

Vitamin C

Vitamin A

Vitamin E

Vitamins D and K

Zinc and Copper

Selenium

Lesser Known Supplements of Interest

References

While most of us can agree that our dialysis patients would benefit from vitamin and/or mineral supplementation, we do not agree on what that supplementation should include. Table 1 provides a comparison of the most common renal vitamins in order to highlight the many options available. As facilities use larger and more efficient dialyzers, there is the potential for increased losses of nutrients making the issue of supplementation even more critical. The Dialysis Outcomes and Practice Patterns Study (DOPPS) looked at medications used in hemodialysis (HD) patients, including the use of water-soluble vitamins.1 The study included 16,345 patients from 308 HD units in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom. The water-soluble vitamins included cobalamin, pyridoxine, ascorbic acid, and folate. After adjusting for factors such as age, sex, race, etc, patients taking the water-soluble vitamins had a 16% lower mortality risk than those not taking any. Although this seems to confirm the belief that patients can benefit from supplementation, it does not answer the main question: what should we be supplementing?

Table 1.

Comparison of Renal Vitamin Supplements

ProductsFolic AcidCobalamin (B12)Pyridoxine (B6)Thiamine (B1)Riboflavin (B2)Niacin (B3)Pantothenic Acid (B5)BiotinVit CVit EIronZincCopperSeleniumOTC/RxAWPDirect Order from the company
Dialyvite 800800mcg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg00000OTC$9.60/100$9.00 / 100 + $3.00 S&H
Dialyvite 800 + Iron800mcg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg029mg000OTC$9.60/100$10.00/100 + $3.00 S&H
Dialyvite 800 + Zn800mcg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg0050mg00OTC$12.00/100$10.00 / 100 + $3.00 S&H
Dialyvite 800 + Zn 15800mcg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg0015mg00OTCN/A$9.50 / 100 + $3.00 S&H
Dialyvite 3000 Rx3mg1mg25mg1.5mg1.7mg20mg10mg300mcg100mg30 IU015mg070mcgRx$19.95/90N/A
Dialyvite Rx1mg6mcg10mg1.5mg1.7mg20mg10mg300mcg100mg00000Rx$9.00/100N/A
Dialyvite Rx + Zinc1mg6mcg10mg1.5mg1.7mg20mg10mg300mcg100mg0050mg00Rx$11.25/100N/A
DiatxZn5mg2mg50mg1.5mg1.5mg20mg10mg300mcg60mg0025mg1.5mg0Rx$48.94/90N/A
Folbee Plus5mg1mg50mg1.5mg1.5mg20mg10mg300mcg60mg00000Rx$43.08/90N/A
NephPlex Rx§1mg6mcg10mg1.5mg1.7mg20mg10mg300mcg30mg0012.5mg00Rx$28.00/100N/A
NephroCaps#1mg6mcg10mg1.5mg1.7mg20mg5mg150mcg100mg00000Rx$24.90/100N/A
Nephronex Liquid⁎⁎900mcg10mcg10mg1.5mg1.7mg20mg10mg300mcg60mg00000OTC$15.99/236 mlN/A
Nephro-Vite††800mcg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg00000OTC$16.54/100N/A
Nephro-Vite Rx††1mg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg00000Rx$54.17/100N/A
Renaltab II‡‡1mg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg00000OTCN/A$14.00 / 120 + No S&H
Renaltab Zn‡‡1mg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg0015mg00OTCN/A$14.00 / 120 + No S&H
RenaPlex§800mcg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg0012.5mg00OTCN/A$8.00 / 100 + $3.95 S&H
Renavit§§800mcg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg00000OTC$13.99/100$13.48 / 90 + $4.00 S&H
Renavit 50mg§§800mcg6mcg10mg1.5mg1.7mg20mg10mg300mcg60mg0050mg00OTCN/A$18.57 / 90 + $4.00 S&H
Renax##2.5mg12mcg15mg3mg2mg20mg10mg300mcg50mg35 IU020mg070mcgRx$47.15/90N/A

Abbreviations: N/A = not available; OTC = over the counter; Rx = prescription; AWP = average wholesale price, S&H = shipping and handling

Note: The manufacturer, address, phone number, web site and/or e-mail address are listed for each product.

Hillestad Pharmaceuticals Inc, Woodruff, Wl, (866) 358-9773, www.hillestadlabs.com, dialyvite@hillestadlabs.com

Pamlab, Covington, LA, (985) 893-4097, www.pamlab.com

Breckenridge Pharmaceutical Inc, Boca Raton, FL, (800) 367-3395. www.folbeeplus.com

§

Nephro-Tech Inc, Shawnee, KS, (800) 879-4755, www.nephrotech.com, info@nephrotech.com

#

Fleming & Company Pharmaceuticals, Fenton, MO, (800) 343-0164, www.flemingcompany.com

⁎⁎

Llorens Pharmaceuticals, Miami, FL, (866) 595-5598, www.llorenspharm.com

††

Watson Pharmaceuticals Inc, Morristown, NJ, (800) 272-5525, www.watsonpharm.com

‡‡

Renalab, Irvine, CA, (800) 345-3838, www.renalabs.com, renalab@cox.net

§§

Integrative Therapeutics Inc, Lake Oswego, OR, (800) 931-1709, www.integrativeinc.com

##

Everett Laboratories Inc, West Orange, NJ, (973) 324-0200, www.everettlabs.com AWP data from the 2005 Drug Topics Red Book, Medical Economics, Thomson Healthcare. Direct Order prices from company websites, customer service representatives, and/or product brochures.

Thiamin (B1), Riboflavin (B2), Pantothenic Acid (B5) 

return to Article Outline

Studies vary regarding thiamin, with some recommending no supplementation to others recommending 1.5 mg/day.2, 3, 4 There may be an increased need for thiamine in chronic ambulatory peritoneal dialysis (CAPD) patients, possibly due to the glucose content of the dialysis solution.5 Riboflavin is similar to thiamin in that studies vary from no recommended supplementation to supplementation of 1.7 mg/day.4, 6 While research has been published on thiamin and riboflavin using amounts above 1.5 mg/day and 1.7 mg/day, respectively, there is no evidence of beneficial effects using larger doses with the possible exception of thiamine in CAPD patients. Information is limited regarding pantothenic acid in dialysis patients, so recommendations are generally 10 mg/day.4

Niacin (B3) 

return to Article Outline

Niacin can refer to either nicotinic acid or nicotinamide (niacinamide), even though they have different pharmacological uses. Niacin as nicotinic acid is sometimes used as a treatment for dyslipidemia.7 Nicotinamide does not work for treating dyslipidemia, but Takahashi et al looked at suppression of hyperphosphatemia using this form.8 The study used nicotinamide daily for 12 weeks and the starting dose was 500 mg/day with the mean dose being 1080 mg/day. Although it was successful, there are some concerns regarding the results. The study only lasted 12 weeks while using large doses. Nicotinamide does not cause the flushing associated with nicotinic acid, but there have been reports of elevated liver tests and liver damage when used in extremely high doses.9 While nicotinamide may potentially offer another treatment option for hyperphosphatemia, further research should be done before routinely recommending doses above the standard 20 mg/day.

Folic Acid, Cobalamin (B12), Pyridoxine (B6) 

return to Article Outline

Folic acid, cobalamin, and pyridoxine are important for development of red blood cells as well as homocysteine pathways.10, 11 Hyperhomocysteinemia is common and may affect as many as 85%-94% of dialysis patients.12 Areas of concern for folic acid supplementation include antagonism of antifolate medications and masking of pernicious anemia.13 Folic acid doses of 5-30 mg have been linked with interference of anticonvulsant drugs such as diphenylhydantoin, which is used to treat epilepsy.13 The pernicious anemia masking effect is unlikely in doses up to 1 mg/day but will occur at 5 mg/day.13 It is unknown where the cut-off for partial to full masking falls in the 1-5 mg/day range. If supplementing folic acid above 1 mg/day, make sure the patient has either been evaluated for pernicious anemia or is receiving enough cobalamin to negate any masking effect. As pernicious anemia can be treated with supplementation of 1000 mcg cobalamin, this should be enough to prevent any masking effects.14 In diabetic neuropathy, improvement was noted in numbness, loss of sensation, and muscle cramps when methylcobalamin was supplemented at 500 mcg 3 times daily for 4 months.15 Atrophic gastritis and certain medications can increase the risk of cobalamin deficiency due to decreased acid secretion. However, the decrease in acid does not affect cobalamin found in fortified foods and supplements.16

High-flux/high-efficiency dialysis increases the clearance of pyridoxine.12 Pyridoxine deficiency can contribute to symptoms of peripheral neuropathy.17 In one study, 56% of unsupplemented patients receiving high-efficiency dialysis were deficient in this vitamin.11 Supplementation of pyridoxine can interfere with the effectiveness of levodopa, used to treat Parkinson’s Disease, although this effect is negated if carbidopa is administered along with the levodopa. Supplementation of pyridoxine should contain at least 10 mg/day, whereas those patients receiving high-flux/high-efficiency dialysis may need more than 15-20 mg/day.4, 10, 18

Biotin 

return to Article Outline

Biotin has been studied in HD patients in regard to both diabetes and neurologic disorders. Two studies of interest used 10 mg/day with 9 patients and 50 mg postdialysis with 11 patients.19, 20 The results help support the beneficial effects of biotin treatment for both diabetes mellitus and uremic neurologic disorders. For routine supplementation, 300 mcg is recommended.4 If treating for restless legs and other uremic neurologic disorders, 10-20 mg/day may be used.21 Biotin is considered safe in doses up to 200 mg/day and it may take 1-3 months of treatment for symptoms to show improvement.21

Vitamin C 

return to Article Outline

Vitamin C works as an antioxidant by being an electron donor.22 Vitamin E’s antioxidant function depends upon Vitamin C, which regenerates alpha-tocopherol and thus allows maintenance of Vitamin E in its nonradical form. Plasma vitamin C levels are lower in HD patients and are subject to increased oxidation rates during dialysis sessions.23 Vitamin C can be metabolized to oxalate and deposition of oxalate crystals in tissues may be a concern.4, 24 While plasma oxalate in HD and peritoneal dialysis (PD) patients have been found to be greater than in normal subjects, the causes are unknown.25 Oxalate is removed at a higher rate from HD patients versus control subjects, which leads to one conclusion that the increased levels are not due to a poor removal process but possibly increased oxalate synthesis or gastrointestinal absorption.25 The issue is further clouded by the difficulty in interpreting and comparing studies dealing with Vitamin C and oxalate. Depending on how the samples were handled, oxalate levels could be falsely elevated due to conversion of ascorbic acid to oxalate during the analysis phase.4, 24, 26 For instance, in CAPD, the fluid has a dwell time that allows oxalate generation from ascorbate to occur in the peritoneum, which will affect any measurements of oxalate removal or clearance.26 Conversions occurring after samples are drawn may explain a major part of the discrepancy between some earlier studies and those more recently completed.26 The issue of adverse effects associated with long-term supplementation of doses above 60-100 mg/day is unclear. For some, the possible risk of larger doses may be outweighed by the antioxidant and wound healing benefits of this vitamin. Vitamin C is further discussed in the Vitamin E section because of the integral relationship between these two antioxidants.

Vitamin A 

return to Article Outline

Vitamin A is important because of its role in vision, growth, and the immune system.27 The most common sign of deficiency is night blindness, whereas toxicity manifests as liver damage, bone abnormalities and joint pain, alopecia, headaches, and vomiting.28 Signs of toxicity of special note for dialysis patients also include anemia, hypertriglyceridemia, and hypercalcemia. It is believed that the hypercalcemia is caused by an increase in osteolytic activity.29 Often patients not receiving Vitamin A supplements will still have increased levels of serum retinol in relation to those without renal disease.4 To complicate matters, Aguilera et al studied PD patients and found elevated plasma retinol in combination with intracellular and clinical signs of hypovitaminosis A, which they hypothesized may be due to disorders with vitamin/carrier complexes.30 These disorders could lead to a mobilization of select vitamins from pool and target cells thereby increasing blood levels while at the same time depleting intracellular levels. This may affect not only Vitamin A but Vitamin E as well.

Vitamin E 

return to Article Outline

Miller et al published a meta-analysis that found supplementation of Vitamin E above 400 IU/day was associated with increased mortality.31 The results need to be viewed with caution though, because there was a lack of consistency between the studies reviewed. Variances between studies involved such things as the form of Vitamin E used, Vitamin E treatment alone versus in combination with other vitamins or minerals, and dosages ranging from 16.5 IU/day to 2000 IU/day.

Khajehdehi et al looked at supplementation of Vitamins E and C for the treatment of cramping in HD patients.32 The study lasted 8 weeks and used 400 mg (∼600 IU) Vitamin E and 250 mg Vitamin C. What they found was that using Vitamin E or Vitamin C alone helped with cramps, but combination treatment with both vitamins worked the best. Vitamin C supplementation may be associated with increased oxalate production, as discussed earlier, but no side effects such as increased urinary stone formation were seen in this trial. The authors concluded that short-term treatment with the combination of both Vitamin E and Vitamin C was safe and successful for treating HD-related cramps but that the safety of long-term treatment was unknown.32

Oxidative stress, which is frequently found in dialysis patients, has been proposed as one contributor to shortened red blood cell (RBC) survival.33 RBC levels of Vitamin E can be decreased even when serum levels are within normal range, which is of special concern for erythropoietin treatment.33 Cristol et al supplemented patients with 500 mg/daily (∼750 IU) of Vitamin E for 6 months and found that erythropoietin needs were reduced by 20%-30%, as compared to initial doses, while still maintaining target hemoglobin levels.33 The authors suggest that the decrease in erythropoietin needs may have been due to Vitamin E’s antioxidant properties. Vitamin E was chosen over Vitamin C as the antioxidant used due to concerns regarding oxalate production, but supplementation with Vitamin C may have produced similar results. It was suggested that supplementation of an antioxidant should occur in HD patients.33 Yonova et al also recommend treatment of oxidative stress in all dialysis patients with more aggressive treatment aimed at those on HD versus PD.34

Vitamins D and K 

return to Article Outline

Vitamin K usually does not need to be supplemented in dialysis patients. An exception may be if the patient has been receiving chronic antibiotic treatment since antibiotics can deplete the beneficial bacteria of the intestinal tract. If a patient has been treated chronically with antibiotics and has an unexplained elevation of prothrombin time, Vitamin K should be evaluated.4 Care should be taken for those patients receiving coumadin or aspirin since they are Vitamin K antagonists. Vitamin D can no longer be converted to its active form by the kidney, so the presence of its inactive form in an oral vitamin supplement is unnecessary.

Zinc and Copper 

return to Article Outline

Zinc is used in over 300 enzymes as well as being involved in the immune system.35 Signs of deficiency include blunting of taste and smell, anorexia, skin changes, hair loss, diarrhea, negative nitrogen balance, immune dysfunction, and glucose intolerance.19, 36 Studies involving trace elements such as zinc and copper are difficult because serum and sometimes erythrocyte or tissue levels do not always reflect the true status and a deficiency can still be present.36 Depletion studies suggest that alterations in immune response occur before plasma reductions become evident.35

There is a positive correlation between protein catabolic rate (PCR) and serum zinc concentration.37 Atkin-Thor et al found that zinc supplementation resulted in taste acuity improvement in 95% of patients, improved appetites, and an increase in average caloric intake of 675 kcal/day.38 Chevalier et al also had similar results in that patients supplemented with 50 mg/day of elemental zinc showed an increased intake of 297 kcal/day.39 Zinc and copper are not lost during dialysis, which suggests that decreased levels are most likely due to causes other than dialysis itself.40 Zinc intakes of 50 mg/day will affect copper indexes such as Cu/Zn-superoxide dismutase.35 Because copper also plays a role in the immune system, it is important to be cautious with long-term zinc supplementation.35 Only a few cases of acute poisoning have been reported after ingestion of 4-8 g of zinc and are characterized by nausea, vomiting, diarrhea, fever, and lethargy.35

Selenium 

return to Article Outline

Selenium acts in conjunction with Vitamin E to protect cell membranes against oxidative damage.41 Signs of deficiency include muscle weakness, myalgia, and congestive heart failure.41 Much of the interest in selenium relates to its role as an antioxidant. Dialysis patients often have low antioxidant levels and show evidence of oxidative stress including increased lipid peroxidation.42 Bonomini et al supplemented selenium at levels of 500 mcg 3 times per week for 3 months and then at 200 mcg 3 times per week for the following 3 months with no apparent side effects.43 The authors concluded that chronic uremic patients could benefit from moderate and safe selenium supplementation.

Lesser Known Supplements of Interest 

return to Article Outline

More recent supplements of interest include CoQ10 and L-Carnitine. CoQ10 is an antioxidant that helps regenerate alpha-tocopherol. Decreased levels are found in multiple disease states.44

L-Carnitine therapy has been associated with suppression of inflammation with reduced c-reactive protein (CRP) concentrations and increased serum albumin, transferrin, blood hemoglobin, and body mass index (BMI).45 Some nephrologists and dietitians are already recommending CoQ10 and L-Carnitine, so expect to hear more about them in the future.

References 

return to Article Outline

1. 1 Andreucci VE , Fissell RB , Bragg-Gresham JL , et al.   Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients . Am J Kidney Dis . 2004;44(Suppl 2):S61–S67 .

2. 2 Niwa T , Ito T , Matsui E , et al.   Plasma level and transfer capacity of thiamin in patients undergoing long-term dialysis . Am J Clin Nutr . 1975;28:1105–1109 (abstr) . MEDLINE

3. 3 Frank T , Czeche K , Bitsch R , et al.   Assessment of thiamin status in chronic renal failure patients, transplant recipients and hemodialysis patients receiving a multivitamin supplementation . Int J Vitam Nutr Res . 2000;70:159–166 (abstr) . MEDLINE

4. 4 Rocco MV , Makoff R . Appropriate vitamin therapy for dialysis patients . Semin Dial . 1997;10:272–277 . CrossRef

5. 5 Pietrzak I . Vitamin disturbances in chronic renal insufficiency (I. Water soluble vitamins) . [article in Polish] Przegl Lek . 1995;52:522–525 (abstr) . MEDLINE

6. 6 Descombes E , Hanck AB , Fellay G . Water soluble vitamins in chronic hemodialysis patients and need for supplementation . Kidney Int . 1993;43:1319–1328 (abstr) . MEDLINE | CrossRef

7. 7 Berra K . Clinical update on the use of niacin for the treatment of dyslipidemia . J Am Acad Nurse Pract . 2004;16:526–534 (abstr) . MEDLINE | CrossRef

8. 8 Takahashi Y , Tanaka A , Nakamura T , et al.   Nicotinamide suppresses hyperphosphatemia in hemodialysis patients . Kidney Int . 2004;65:1099–1104 (abstr) . MEDLINE | CrossRef

9. 9 PDRhealth . Copyright 1996-2004 Thompson Healthcare Inc. Nicotinamide . 2005; Available at http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/nic_0183.shtml Accessed June 28 .

10. 10 The Nephron Information Center . Why You Need Special Vitamins. Courtesy of R & D Laboratories . 2005; Available at http://nephron.com/vitamins.html Accessed March 30 .

11. 11 Leblanc M , Pichette V , Geadah D , et al.   Folic acid and pyridoxal-5′-phosphate losses during high-efficiency hemodialysis in patients without hydrosoluble vitamin supplementation . J Ren Nutr . 2000;10:196–201 . Abstract | Full-Text PDF (112 KB) | CrossRef

12. 12 Lasseur C , Parrot F , Delmas Y , et al.   Impact of high-flux/high-efficiency dialysis on folate and homocysteine metabolism . J Nephrol . 2001;14:32–35 . MEDLINE

13. 13 Hathcock JN . Vitamin and mineral safety . ed 2. Folic Acid: Council for Responsible Nutrition; 2004; .

14. 14 Kuzminski AM , Del Giacco EJ , Allen RH , et al.   Effective treatment of cobalamin deficiency with oral cobalamin . Blood . 1998;92:1191–1198 . MEDLINE

15. 15 Monograph  . Methylcobalamin . Altern Med Rev . 1998;3:461–463 . MEDLINE

16. 16 FAO WHO . Vitamin B12: Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation . 2002; Chapter 5. Bangkok, Thailand, pp 65-72 .

17. 17 Moriwaki K , Kanno Y , Nakamoto H , et al.   Vitamin B6 deficiency in elderly patients on chronic peritoneal dialysis . Adv Perit Dial . 2000;16:308–312 (abstr) . MEDLINE

18. 18 Locatelli F , Fouque D , Heimburger O , et al.   Nutritional status in dialysis patients (a European consensus) . Nephrol Dial Transplant . 2002;17:563–572 . MEDLINE | CrossRef

19. 19 Yatzidis H , Koutsicos D , Agroyannis B , et al.   Biotin in the management of uremic neurologic disorders . Nephron . 1984;36:183–186 (abstr) .

20. 20 Koutsikos D , Fourtounas C , Kapetanaki A , et al.   Oral glucose tolerance test after high-dose i.v . biotin administration in normoglucemic hemodialysis patients. Ren Fail . 1996;18:131–137 (abstr) .

21. 21 Lutz-Mizar J . Biotin in the treatment of uremic neurologic disorders . Diag Nutr Network 13(2) . 2004; October .

22. 22 FAO WHO . Vitamin C: Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation . 2002; Chapter 6. Bangkok, Thailand, pp 73-86 .

23. 23 Morena M , Cristol J , Bosc J , et al.   Convective and diffusive losses of vitamin C during haemodiafiltration session (a contributive factor to oxidative stress in haemodialysis patients) . Nephrol Dial Transplant . 2002;17:422–427 . MEDLINE | CrossRef

24. 24 Curhan GC , Willett WC , Speizer FE , et al.   Intake of Vitamins B6 and C and the risk of kidney stones in women . J Am Soc Nephrol . 1999;10:840–845 . MEDLINE

25. 25 Costello JF , Sadovnic MJ , Cottington EM . Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal . J Am Soc Nephrol . 1991;1:1289–1298 (abstr) . MEDLINE

26. 26 Costello J , Landwehr DM . Determination of oxalate concentration in blood . Clin Chem . 1988;34:1540–1544 . MEDLINE

27. 27 Hunt SM , Groff JL . The Vitamins . In:  Gomez J editors. Advanced Nutrition and Human Metabolism . St. Paul, MN: West Publishing Company; 1990;p. 226–238 .

28. 28 FAO and WHO: Vitamin A: Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation. Chapter 7. Bangkok, Thailand, 2002, pp 87-107

29. 29 Farrington K , Miller P , Varghese Z , et al.   Vitamin A toxicity and hypercalcaemia in chronic renal failure . BMJ . 1981;282:1999–2002 (abstr) . MEDLINE

30. 30 Aguilera A , Bajo MA , del Peso G , et al.   True deficiency of antioxidant vitamins E and A in dialysis patients (Relationship with clinical patterns of atherosclerosis) . Adv Perit Dial . 2002;18:206–211 (abstr) . MEDLINE

31. 31 Miller ER , Pastor-Barriuso R , Dalal D , et al.   Meta-analysis (high-dosage vitamin E supplementation may increase all-cause mortality) . Ann Intern Med . 2005;142:37–46 (abstr) .

32. 32 Khajehdehi P , Mojerlou M , Behzadi S , et al.   A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps . Nephrol Dial Transplant . 2001;16:1448–1451 . MEDLINE | CrossRef

33. 33 Cristol JP , Bosc JY , Badiou S , et al.   Erythropoietin and oxidative stress in haemodialysis (beneficial effects of vitamin E supplementation) . Nephrol Dial Transplant . 1997;12:2312–2317 . MEDLINE | CrossRef

34. 34 Yonova D , Trendafilov I , Papazov V , et al.   Comparative study of oxidative stress in peritoneal dialysis and hemodialysis patients . Hippokratia . 2004;8:170–172 .

35. 35 FAO WHO . Zinc: Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation . 2002; Chapter 16. Bangkok, Thailand, pp 257-270 .

36. 36 Sriram K , Abraham G . Loss of zinc and selenium does not occur through peritoneal dialysis . Nutrition . 2000;16:1047–1051 . Abstract | Full Text | Full-Text PDF (42 KB) | CrossRef

37. 37 Jern NA , VanBeber AD , Gorman MA , et al.   The effects of zinc supplementation on serum zinc concentration and protein catabolic rate in hemodialysis patients . J Ren Nutr . 2000;10:148–153 (abstr) . Abstract | Full-Text PDF (45 KB) | CrossRef

38. 38 Atkin-Thor E , Goddard BW , O’Nion J , et al.   Hypogeusia and zinc depletion in chronic dialysis patients . Am J Clin Nutr . 1978;31:1948–1951 (abstr) . MEDLINE

39. 39 Chevalier CA , Liepa G , Murphy MD , et al.   The effects of zinc supplementation on serum zinc and cholesterol concentrations in hemodialysis patients . J Ren Nutr . 2002;12:183–189 . Abstract | Full Text | Full-Text PDF (83 KB) | CrossRef

40. 40 Sen S , Bor NM , Colakoglu M , et al.   Clearance of zinc and copper during hemodialysis (Preliminary study) . J Islamic Academy Sci . 1991;4:265–267 .

41. 41 FAO WHO . Selenium: Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation . 2002; Chapter 15. Bangkok, Thailand, pp 235-255 .

42. 42 Loughrey CM , Young IS , Lightbody JH , et al.   Oxidative stress in haemodialysis . QJM . 1994;87:679–683 (abstr) . MEDLINE

43. 43 Bonomini M , Forster S , DeRisio F , et al.   Effects of selenium supplementation on immune parameters in chronic uraemic patients on haemodialysis . Nephrol Dial Transplant . 1995;10:1654–1661 (abstr) . MEDLINE

44. 44 Siemieniuk E , Skrzydlewska E . Coenzyme Q10 (Its biosynthesis and biological significance in animal organisms and in humans) . Postepy Hig Med Dosw . 2005;59:150–159 (abstr) .

45. 45 Savica V , Santoro D , Mazzaglia G , et al.   L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients . J Ren Nutr . 2005;15:225–230 . Abstract | Full Text | Full-Text PDF (149 KB) | CrossRef

a Renal Dietitian, Fresenius Medical Care North America, FMC Morgan County, Martinsville, IN

b FMC Blue River Valley Dialysis, Shelbyville, IN

Corresponding Author InformationAddress reprint requests to Pam Buchholz, RD, CD, Fresenius Medical Care North America, FMC Morgan County, 2200 John R. Wooden Dr, Suite 106, Martinsville, IN 46151

 Column Editor: Maria Karalis, MBA, RD, LD

PII: S1051-2276(05)00186-X

doi:10.1053/j.jrn.2005.12.001


View previous. 25 of 25